Humana Inc. (NYSE:HUM) is Sustainable Insight Capital Management LLC’s 6th Largest Position

Sustainable Insight Capital Management LLC increased its holdings in shares of Humana Inc. (NYSE:HUM) by 15.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 39,830 shares of the insurance provider’s stock after buying an additional 5,300 shares during the quarter. Humana comprises approximately 5.7% of Sustainable Insight Capital Management LLC’s portfolio, making the stock its 6th biggest holding. Sustainable Insight Capital Management LLC’s holdings in Humana were worth $12,616,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Atria Investments Inc increased its holdings in shares of Humana by 18.1% during the 3rd quarter. Atria Investments Inc now owns 5,552 shares of the insurance provider’s stock worth $1,759,000 after buying an additional 851 shares during the last quarter. Demars Financial Group LLC lifted its stake in shares of Humana by 2.7% in the 3rd quarter. Demars Financial Group LLC now owns 1,950 shares of the insurance provider’s stock valued at $618,000 after purchasing an additional 52 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Humana by 19.4% during the 3rd quarter. Assetmark Inc. now owns 14,723 shares of the insurance provider’s stock worth $4,663,000 after purchasing an additional 2,392 shares during the period. Principal Financial Group Inc. increased its position in Humana by 2.4% during the 3rd quarter. Principal Financial Group Inc. now owns 170,636 shares of the insurance provider’s stock worth $54,047,000 after purchasing an additional 3,961 shares in the last quarter. Finally, Sentry Investment Management LLC purchased a new position in Humana in the third quarter valued at approximately $179,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Trading Up 0.1 %

Shares of NYSE HUM opened at $288.12 on Friday. The stock has a market capitalization of $34.69 billion, a P/E ratio of 25.52, a PEG ratio of 2.28 and a beta of 0.52. The stock’s 50 day moving average price is $289.38 and its two-hundred day moving average price is $332.67. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $527.18.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, analysts anticipate that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research reports. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research note on Thursday, October 3rd. Truist Financial lowered their price target on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a report on Friday, October 11th. Oppenheimer cut their price objective on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Finally, Stephens reiterated an “equal weight” rating and set a $250.00 target price on shares of Humana in a report on Wednesday, October 9th. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $315.86.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.